Category: AstraZeneca’s late-stage trial failure sends its shares down 16% and Bristol-Myers

AstraZeneca’s late-stage trial failure sends its shares down 16% and Bristol-Myers, Merck stocks seesawing

  1. AstraZeneca’s late-stage trial failure sends its shares down 16% and Bristol-Myers, Merck stocks seesawing  MarketWatch
  2. Did the Checkpoint Inhibitor Bubble Just Burst?  Motley Fool
  3. Bristol-Myers Squibb (BMY) Q2 2017 Results – Earnings Call Transcript  Seeking Alpha
  4. Full coverage

from Business – Google News http://www.marketwatch.com/story/astrazenecas-late-stage-trial-failure-sends-its-shares-down-16-and-bristol-myers-merck-stocks-seesawing-2017-07-27

Advertisements

AstraZeneca’s late-stage trial failure sends its shares down 16% and Bristol-Myers, Merck stocks seesawing

  1. AstraZeneca’s late-stage trial failure sends its shares down 16% and Bristol-Myers, Merck stocks seesawing  MarketWatch
  2. Risk Aversion, AstraZeneca Weigh on Health Care Sector — Health Care Roundup  Fox Business
  3. Did the Checkpoint Inhibitor Bubble Just Burst?  Motley Fool
  4. Full coverage

from Business – Google News http://www.marketwatch.com/story/astrazenecas-late-stage-trial-failure-sends-its-shares-down-16-and-bristol-myers-merck-stocks-seesawing-2017-07-27

AstraZeneca’s late-stage trial failure sends its shares down 16% and Bristol-Myers, Merck stocks seesawing

  1. AstraZeneca’s late-stage trial failure sends its shares down 16% and Bristol-Myers, Merck stocks seesawing  MarketWatch
  2. Bristol-Myers slides with Wall St eyeing key cancer drug  Financial Times
  3. Morning Movers: Bristol-Myers Sinks, Barrick Climbs, Alexion Soars  Barron’s
  4. Full coverage

from Business – Google News http://www.marketwatch.com/story/astrazenecas-late-stage-trial-failure-sends-its-shares-down-16-and-bristol-myers-merck-stocks-seesawing-2017-07-27